September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Tocilizumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis
Author Affiliations & Notes
  • Christoph Tappeiner
    Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
    Department of Ophthalmology at St. Franziskus Hospital, Muenster, Germany
  • Marina Mesquida
    Institut Clinic d’ Oftalmologia, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
  • Alfredo Adan Civera
    Institut Clinic d’ Oftalmologia, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
  • Jordi Anton Lopez
    Pediatric Rheumatology Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain
  • Athimalaipet Ramanan
    Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, United Kingdom
  • Ester Carreno
    Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, United Kingdom
  • Kaisu Kotaniemi
    Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland
  • Joke H. de Boer
    Department of Ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands
  • Arnd Heiligenhaus
    Department of Ophthalmology at St. Franziskus Hospital, Muenster, Germany
  • Footnotes
    Commercial Relationships   Christoph Tappeiner, None; Marina Mesquida, None; Alfredo Adan Civera, None; Jordi Anton Lopez, None; Athimalaipet Ramanan, None; Ester Carreno, None; Kaisu Kotaniemi, None; Joke H. de Boer, None; Arnd Heiligenhaus, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1875. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christoph Tappeiner, Marina Mesquida, Alfredo Adan Civera, Jordi Anton Lopez, Athimalaipet Ramanan, Ester Carreno, Kaisu Kotaniemi, Joke H. de Boer, Arnd Heiligenhaus; Tocilizumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1875.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze the efficacy of the anti-IL-6R antibody tocilizumab (TCZ) for the treatment of severe and refractory chronic uveitis associated with juvenile idiopathic arthritis (JIA).

Methods : This retrospective analysis was performed by members of the multinational interdisciplinary working group for uveitis in childhood (MIWGUC). JIA patients receiving TCZ treatment due to active and refractory uveitis were included in this analysis. JIA and related uveitis data (disease onset, activity, structural complications, topical and systemic anti-inflammatory treatment, eye surgery) at TCZ start (baseline), and at 3, 6, 9, and 12 months after TCZ start were evaluated.

Results : A total of 17 patients (14 female) with active uveitis (n=17) were included (mean age 15.3 ± 6.9 years, mean follow-up time 8.4 months). In all patients, uveitis had been refractory to previous topical and systemic corticosteroids, methotrexate and other synthetic disease modifying drugs, and at least one TNF-alpha inhibitor. Uveitis inactivity was achieved in 10 patients after a mean of 5.7 months of TCZ treatment (in 3 of them recurrence later on), and remained active in another 7 patients. Macular edema was present in 5 patients at baseline, and improved in all of them under TCZ treatment. Arthritis was active in 10 patients at initial visit, and in 5 patients at final visit.

Conclusions : TCZ may be a therapeutic option for selected patients with severe JIA associated uveitis that has been refractory to methotrexate and TNF inhibitors.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×